TARA vs. ARCT, CMPX, ETON, ALMS, PRTA, CRVS, ERAS, ITOS, SLDB, and ATXS
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Eton Pharmaceuticals (ETON), Alumis (ALMS), Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry.
Protara Therapeutics vs. Its Competitors
Arcturus Therapeutics (NASDAQ:ARCT) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.
Protara Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arcturus Therapeutics had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.78 beat Arcturus Therapeutics' score of 1.46 indicating that Protara Therapeutics is being referred to more favorably in the news media.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 15.3% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 12.5% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Arcturus Therapeutics has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Arcturus Therapeutics currently has a consensus target price of $50.57, suggesting a potential upside of 178.94%. Protara Therapeutics has a consensus target price of $19.60, suggesting a potential upside of 520.25%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Arcturus Therapeutics.
Protara Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. Arcturus Therapeutics' return on equity of -24.87% beat Protara Therapeutics' return on equity.
Summary
Arcturus Therapeutics and Protara Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TARA) was last updated on 9/16/2025 by MarketBeat.com Staff
